Advisory Cmte. Endorses Cinryze Unanimously, But HAE Battle Continues
Executive Summary
Even with a unanimous endorsement from FDA's Blood Products Advisory Committee, Lev Pharmaceuticals' hereditary angioedema candidate Cinryze has an uncertain future because of competitive pressure - as several companies are racing to win FDA's orphan drug exclusivity for HAE
You may also be interested in...
Cinryze Prophylaxis Approval Leaves Window For HAE Treatment Contenders
The approval of ViroPharma/Lev's hereditary angioedema therapyCinryze on Oct. 10, with orphan status for prophylaxis only, leaves the window open for other C1 esterase inhibitors to claim the prize of orphan exclusivity for treatment of acute attacks. But ViroPharma thinks it can win that too
Cinryze Prophylaxis Approval Leaves Window For HAE Treatment Contenders
The approval of ViroPharma/Lev's hereditary angioedema therapyCinryze on Oct. 10, with orphan status for prophylaxis only, leaves the window open for other C1 esterase inhibitors to claim the prize of orphan exclusivity for treatment of acute attacks. But ViroPharma thinks it can win that too
ViroPharma Makes Smart Bet On Split Indications For HAE With Lev Deal
ViroPharma's proposed acquisition of Lev Pharmaceuticals covers contingencies for the various regulatory outcomes for Lev's crown jewel, the hereditary angioedema therapy Cinryze, including a possible escape hatch